# Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

> **NCT00801931** · PHASE1,PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 1 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Neuroblastoma
- Immunodeficiencies
- Anemia

## Interventions

- **DRUG:** Alemtuzumab
- **RADIATION:** Total Body Irradiation
- **DRUG:** Melphalan
- **DRUG:** Busulfan
- **DRUG:** Phenytoin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Horse Antithymocyte Globulin
- **DRUG:** Rabbit Antithymocyte Globulin
- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT00801931
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09-06
- **Primary completion:** 2009-05-05
- **Final completion:** 2009-05-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801931, "Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00801931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*